The squad departed for London in different groups in the last few days, with the full group set to assemble in the UK on Monday morning.
The Springboks will face Japan at Wembley Stadium on Saturday 1 November,…

The squad departed for London in different groups in the last few days, with the full group set to assemble in the UK on Monday morning.
The Springboks will face Japan at Wembley Stadium on Saturday 1 November,…

Physicists at MIT have introduced a technique to study the interior of an atom’s nucleus by relying on the atom’s own electrons as “messengers” inside a molecule.
In research published on October 23 in Science, the team precisely measured the…

LOS ANGELES (AP) — A big-screen adaptation of the popular anime “Chainsaw Man” has beaten out a biopic about the Boss and the horror sequel “Black Phone 2” to top the North American box office.
It’s the latest win for an anime film, less…

Pakistan army on Sunday said that five of its soldiers and 25 militants were killed during border clashes with Afghanistan.These attacks occurred while Afghan and Pakistani officials met in Istanbul amid a recent ceasefire agreement.“These…

A groundbreaking study is taking a fresh look at one of science’s oldest questions: how did life arise from nonliving material on early Earth? Researcher Robert G. Endres of Imperial College London has created a new mathematical framework…

Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.
Bloomberg | Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.
A deal could be announced as early as Sunday, the report said.
Novartis and Avidity didn’t immediately respond to CNBC’s requests for comment.
Avidity specializes in developing an innovative class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates. RNA-based therapeutics are a relatively new class of medications that work by altering how genes are expressed to treat or prevent diseases.
The reported discussions come as Novartis ramps up its research and development division. The company earlier this year pledged to invest $23 billion to build out its U.S.-based infrastructure, which includes plans to construct a second R&D hub in San Diego.
The company has also struck two key deals with Anthos Therapeutics and Regulus Therapeutics this year to boost its development and manufacturing of cardiovascular and kidney disease drugs.
Avidity shares closed at $49.15 on Friday. The stock, which has a market capitalization of roughly $7.2 billion, is up nearly 70% since the beginning of the year. Novartis shares closed at $130.36 on Friday.
Read the complete Bloomberg News report here.

Radiohead frontman Thom Yorke told the UK’s Sunday Times that he won’t play in Israel again while Prime Minister Benjamin Netanyahu is in power, and that Israel should not be part of Eurovision, while also criticizing pro-Palestinian…

The rapid evolution of AI video generation has reshaped how creators, educators, and marketers produce visual content. In this fast-moving landscape, models like Wan 2.2 laid the foundation for prompt-based video creation —…